For Immediate Release
Chicago, IL – November 29, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Carlyle Group LP ( CG- Free Report), Blackstone Group LP ( BX- Free Report), Kohlberg Kravis Roberts & Co. L.P. ( KKR- Free Report), Waddell & Reed Financial, Inc. ( WDR- Free Report) and GlaxoSmithKline ( GSK- Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Wednesday’s Analyst Blog:
Carlyle Group Making New Acquisition
In an attempt to diversify its business, The Carlyle Group LP ( CG- Free Report) recently announced that it will acquire Diversified Global Asset Management Corporation (:DGAM). The acquisition is expected to be complete by Feb 2014.
Carlyle will initially pay $33 million – $25 million in stock and $8 million in cash – for DGAM and then an additional amount of maximum $70 million might be paid over the following seven years, subject to performance of DGAM. Management at DGAM will remain unchanged.
Incepted in 2004, DGAM has roughly $6.7 billion in managed and advised assets. On completion of the acquisition, it will be a part of Carlyle's solutions platform, which includes funds of private equity funds. As a result of this deal, Carlyle's solutions platform will be able to offer diverse investment solutions across hedge funds, private equity and real estate to its clients. The latter had $48.4 billion in assets under management as of Sep 30, 2013.
The deal with DGAM will mark Carlyle's first venture into funds of hedge funds. However, the company already owns 55% stake in three regular hedge funds: credit specialist Claren Road Asset Management; emerging markets investor Emerging Sovereign Group; and commodities expert Vermillion Asset Management.
Following the footsteps of asset manager Blackstone Group LP ( BX- Free Report) and Kohlberg Kravis Roberts & Co. L.P. ( KKR- Free Report), Carlyle has been diversifying its business over the past decade to grow assets and reduce greater dependence on leveraged buyouts. Carlyle recently acquired a 40% stake in Dutch investment manager AlpInvest Partners NV and completed the acquisition of Metropolitan Real Estate Equity Management LLC, a fund-of-funds investor in property.
We believe that Carlyle’s efforts to diversify beyond its traditional business will help to boost earnings amid a volatile operating environment. Also given its sound liquidity and balance sheet position, we expect the company to drive further inorganic growth in the quarters ahead.
Carlyle currently carries a Zacks Rank #3 (Hold). A better-ranked stocks in the same sector include Waddell & Reed Financial, Inc. ( WDR- Free Report), which carries a Zacks Rank #1 (Strong Buy).
Update on Glaxo's Avandia
GlaxoSmithKline’s ( GSK- Free Report) Avandia is available for type II diabetes. Avandia came under the FDA scanner in 2007 after an article in the New England Journal of Medicine (:NEJM) linked the use of Avandia (rosiglitazone) with increased risk of cardiovascular events. Following the report Glaxo revised the U.S. label on Avandia.
In 2010, the European Medicines Agency (:EMA) banned Avandia, while the FDA severely restricted the use of the drug. Annual sales of Avandia have fallen drastically to £6 million (in 2012) from £1.6 billion in 2006.
In Nov 2013, Glaxo announced that the U.S. Food and Drug Administration (:FDA) has eased the restrictions on Avandia use. The FDA has suggested label modification about cardiovascular safety apart from certain changes to the Risk Evaluation and Mitigation Strategy (:REMS) program. The FDA has waived the post market study requirement.
In Jun 2013, the joint advisory committee (comprising the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee) to the FDA voted in favor of easing safety restrictions related to Avandia.
Of the 26-member panel, 13 voted in favor of modifying and 7 in favor of removing the Avandia REMS program. However, 5 members were in favor of continuing the REMS and 1 recommended removal of Avandia from the U.S. market.
We remind investors that the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (:RECORD) trial did not show an elevated risk of heart attack or death in patients being treated with Avandia versus standard diabetes therapies.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on CG - FREE
Get the full Report on BX - FREE
Get the full Report on KKR - FREE
Get the full Report on WDR - FREE
Get the full Report on GSK - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
For Immediate Release